Chimerism analysis following nonmyeloablative stem cell transplantation
T Lion, F Watzinger - Myeloid Leukemia: Methods and Protocols, 2006 - Springer
Molecular monitoring of hematopoietic chimerism has become a routine diagnostic
approach in patients after allogeneic stem cell transplantation. Chimerism testing permits the …
approach in patients after allogeneic stem cell transplantation. Chimerism testing permits the …
Dynamics of lineage-restricted mixed chimerism following sex-mismatched allogeneic bone marrow transplantation.
J Thiele, C Wickenhauser, HM Kvasnicka… - Histology and …, 2003 - europepmc.org
Scant knowledge is available about the dynamics of lineage-specific mixed chimerism (Ch)
following bone marrow transplantation (BMT). This review is focused on findings derived …
following bone marrow transplantation (BMT). This review is focused on findings derived …
Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
T Lion, T Henn, A Gadner, A Gaiger, P Kalhs - The Lancet, 1993 - Elsevier
In patients with chronic myelogenous leukaemia (CML) treated by allogeneic bone marrow
transplantation (BMT), detection of residual leukaemic cells carrying the characteristic …
transplantation (BMT), detection of residual leukaemic cells carrying the characteristic …
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after …
J Mattsson, M Uzunel, L Tammik, J Aschan, O Ringden - Leukemia, 2001 - nature.com
One of the major complications after allogeneic stem cell transplantation (SCT) in patients
with malignant disease is a high frequency of relapse. We have prospectively analyzed the …
with malignant disease is a high frequency of relapse. We have prospectively analyzed the …
Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow …
M Lee, I Khouri, R Champlin… - British journal of …, 1992 - Wiley Online Library
The prognostic significance of detecting minimal residual disease by polymerase chain
reaction (PCR) amplification of bcr/abl mRNA transcripts was investigated in 27 bone …
reaction (PCR) amplification of bcr/abl mRNA transcripts was investigated in 27 bone …
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation
JG Zhang, F Lin, A Chase, JM Goldman, NC Cross - 1996 - ashpublications.org
To test whether patients in remission after allogeneic bone marrow transplantation (BMT)
possess a pool of chronic myeloid leukemia (CML) cells that do not express BCR-ABL …
possess a pool of chronic myeloid leukemia (CML) cells that do not express BCR-ABL …
Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for testing in different clinical–biological situations
T Lion - Leukemia, 2001 - nature.com
The monitoring of chimerism has become a routine diagnostic instrument at centers
performing allogeneic stem cell or bone marrow transplantation. Despite the widespread …
performing allogeneic stem cell or bone marrow transplantation. Despite the widespread …
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR …
C Thiede, M Bornhäuser, U Oelschlägel, C Brendel… - Leukemia, 2001 - nature.com
Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT)
has been shown to be predictive for graft failure and relapse. We have explored the impact …
has been shown to be predictive for graft failure and relapse. We have explored the impact …
Molecular remission of chronic myeloid leukaemia following a non‐myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a …
R Childs, D Epperson, E Bahceci… - British journal of …, 1999 - Wiley Online Library
Two patients with chronic myeloid leukaemia (CML) received a non‐myeloablative
preparative regimen of cyclophosphamide and fludarabine, followed by an unmanipulated …
preparative regimen of cyclophosphamide and fludarabine, followed by an unmanipulated …